All In Biotech

Drug Trial Radar · NCT04040634

Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)

Large-Scale Randomized Clinical Trial Assessing Intensive Blood Pressure Control for Reduction of Major Cardiovascular Events in Patients With Diabetes Mellitus (OPTIMAL-DIABETES)

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 9,476 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,476

Actual

Start

Aug 8, 2019

Primary completion

Jul 8, 2026

Study completion Jul 8, 2026

Sponsor

Lead sponsor
Hospital Israelita Albert EinsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Brazil
First posted
Aug 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

High blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly prevalent condition, and it is usually associated with diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events including cardiovascular death, acute myocardial infarction, stroke, unstable angina and heart failure. In addition, high BP is also related to cognitive decline. The OPTIMAL-DIABETES trial consists of a two-arm, multicenter, randomized clinical trial designed to test whether a lower systolic blood pressure (SBP) target will reduce the occurrence of major cardiovascular events in diabetic patients compared to the standard SBP target.

Conditions

  • Diabetes Mellitus
  • High Blood Pressure
  • Cardiovascular Diseases
  • Cognitive Impairment

Interventions

  • Intensive Control of Systolic Blood Pressure (SBP)Drug

    Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine

  • Standard control of Systolic Blood Pressure (SBP)Drug

    The same medications used in the Intensive BP arm will be used for the Standard BP arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failureTime frame: From randomization to 48 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Centro de Pesquisas Clínicas Dr Marco Mota

    Maceió, Alagoas, Brazil

  • Centro de Pesquisas em Diabetes e Doenças Endocrino-Metabólicas

    Fortaleza, Ceará, Brazil

  • Instituto de Estudos E Pesquisas Clinicas Do Ceara

    Fortaleza, Ceará, Brazil

  • Hospital Universitário Cassiano Antonio de Moraes

    Vitória, Espírito Santo, Brazil

  • Hospital Ana Nery

    Salvador, Estado de Bahia, Brazil

  • Instituto Hospital de Base

    Brasília, Federal District, Brazil

  • Universidade Federal de Goiás

    Goiânia, Goiás, Brazil

  • NS Clínica de Diabetes e Endocrinologia Ltda

    Goiânia, Goiás, Brazil

  • Hospital das Clinicas da Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • Centro de Pesquisa do Hospital Santa Lúcia

    Poços de Caldas, Minas Gerais, Brazil

  • Hospital Universitário João de Barros Barreto - UFPA

    Belém, Pará, Brazil

  • Medicina Nuclear Alto da XV

    Curitiba, Paraná, Brazil

  • Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares da Silva

    Recife, Pernambuco, Brazil

  • Faculdade de Ciências Médicas - Universidade do Estado do Rio de Janeiro

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital São Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Endocrinologia Geloneze

    Campinas, São Paulo, Brazil

  • Universidade Estadual de Campinas - UNICAMP

    Campinas, São Paulo, Brazil

  • Indacor Servicos Medicos Ltda

    Indaiatuba, São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

    Ribeirão Preto, São Paulo, Brazil

  • Centro Integrado de Pesquisas

    São José do Rio Preto, São Paulo, Brazil

  • Clínica Vilela & Martin

    São José do Rio Preto, São Paulo, Brazil

  • Instituto de Cardiologia e Endocrinologia Rio Preto Ltda

    São José do Rio Preto, São Paulo, Brazil

  • Clínica de Metabologia e Hipertensão da Universidade Federal de São Paulo

    São Paulo, São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, São Paulo, Brazil

  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, São Paulo, Brazil

  • Instituto Dante Pazzanese de Cardiologia

    São Paulo, São Paulo, Brazil

  • Irmandade Da Santa Casa de Misericordia de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Real e Benemérita Associação Portuguesa de Beneficência/SP

    São Paulo, São Paulo, Brazil

  • Clínica Cardiológica

    Votuporanga, São Paulo, Brazil

  • Santa Casa de Misericordia de Votuporanga

    Votuporanga, São Paulo, Brazil

  • Centro de Pesquisa Clínica do Coração

    Aracaju, Sergipe, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.